journal article·2024-06-01Open access

Nanodrug delivery materials for digestive system diseases

Dan Yang, Huanxuan Zeng, Yuan Zhuang, Shicui Jiang, Wenjie Pan

APL Materials· Volume 12· Issue 6

Abstract

Digestive system diseases, such as gastritis, gastric ulcers, chronic liver disease, inflammatory bowel disease (IBD), and colorectal cancer, represent a major group of diseases that have high morbidity and death rates worldwide. Their incidence continues to rise owing to factors such as dietary structure changes, accelerated lifestyles, increased environmental pollution, and population aging. Despite the rapid development of the medical technology, the treatment of digestive diseases still faces many challenges, such as addressing drug-resistant Helicobacter pylori infections, treating IBD, and improving the efficacy of advanced gastrointestinal tumor therapies. Fortunately, the emergence of drug-releasing materials has provided new insights that can be used in the treatment of digestive disorders. Drug-releasing materials are a category of specially designed carriers or systems capable of carrying drugs and controlling their release at specific time intervals on demand to achieve the desired therapeutic effect. This article reviews recent research progress of drug-releasing materials used to diagnose and treat digestive disorders. First, the limitations of traditional oral drug delivery methods, such as low bioavailability and nonspecific distribution, are discussed. Second, different types of drug-releasing materials, such as liposomes, dendritic polymers, micelles, nanogels, inorganic nanoparticles, and extracellular vesicles, along with their advantages in terms of improved drug stability, biocompatibility, targeting, and controlled release, are outlined. In addition, the application strategies and preclinical findings of various drug release materials for different digestive disorders are discussed in detail. This Review could help researchers explore more advanced nanomaterials for personalized treatment of drug delivery for digestive disorders.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Inhalation and Respiratory Drug Delivery · Helicobacter pylori-related gastroenterology studies · Nanoparticle-Based Drug Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

The Third Affiliated Hospital of Wenzhou Medical University 1 , Wenzhou 325200, China

Ningxia Medical University 2 , Ningxia 750001, China

Liji Medical Research Academy 3 , Ruian, Zhejiang 325200, China

Funding

Zhejiang Province Traditional Chinese Medicine Scientific Project

References (100+)

Show source-provided references
1. Oral liposomal delivery of an activatable budesonide prodrug reduces colitis in experimental mice10.1080/10717544.2023.2183821 ↗
2. Global cancer statistics 2020: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries10.3322/caac.21660 ↗
3. Global burden of digestive diseases: A systematic analysis of the global burden of diseases study, 1990 to 201910.1053/j.gastro.2023.05.050 ↗
4. Recent progress of micro/nanomotors to overcome physiological barriers in the gastrointestinal tract10.1016/j.jconrel.2023.07.005 ↗
5. Oral delivery of micro/nanoparticulate systems based on natural polysaccharides for intestinal diseases therapy: Challenges, advances and future perspectives10.1016/j.jconrel.2021.04.026 ↗
6. Advances in oral drug delivery systems: Challenges and opportunities10.3390/pharmaceutics15020484 ↗
7. Oral nanomedicine biointeractions in the gastrointestinal tract in health and disease10.1016/j.addr.2023.115117 ↗
8. Nanoparticle-mediated drug delivery systems for the treatment of IBD: Current perspectives10.2147/ijn.s210315 ↗
9. The “hand as foot” teaching method in anatomy of the stomach10.1016/j.asjsur.2022.04.050 ↗
10. Novel drug delivery systems for inflammatory bowel disease10.3748/wjg.v28.i18.1922 ↗
11. Current status and advances in esophageal drug delivery technology: Influence of physiological, pathophysiological and pharmaceutical factors10.1080/10717544.2023.2219423 ↗
12. Improving dissolution behavior and oral absorption of drugs with pH-dependent solubility using pH modifiers: A physiologically realistic mass transport analysis10.1021/acs.molpharmaceut.1c00262 ↗
13. In vitro models replicating the human intestinal epithelium for absorption and metabolism studies: A systematic review10.1016/j.jconrel.2021.05.028 ↗
14. A comprehensive review of the strategies to improve oral drug absorption with special emphasis on the cellular and molecular mechanisms10.1016/j.jddst.2020.102178 ↗
15. Initiatives for a healthy stomach10.1007/s11938-019-00266-x ↗
16. Oral delivery of proteins and peptides: Challenges, status quo and future perspectives10.1016/j.apsb.2021.04.001 ↗
17. Interspecies differences in gastrointestinal physiology affecting the in vivo performance of oral pharmaceutical solid dosage forms10.1016/j.jddst.2021.102923 ↗
18. Foundations of gastrointestinal-based drug delivery and future developments10.1038/s41575-021-00539-w ↗
19. Dendrobium huoshanense stem polysaccharide ameliorates alcohol-induced gastric ulcer in rats through Nrf2-mediated strengthening of gastric mucosal barrier10.1016/j.ijbiomac.2023.124001 ↗
20. Oral nanomedicine: Challenges and opportunities10.1002/adma.202306081 ↗
21. Gastrointestinal mucus in dog: Physiological characteristics, composition, and structural properties10.1016/j.ejpb.2022.02.019 ↗
22. Effect of absorption-modifying excipients, hypotonicity, and enteric neural activity in an in vivo model for small intestinal transport10.1016/j.ijpharm.2018.07.057 ↗
23. Size-dependent in vivo transport of nanoparticles: Implications for delivery, targeting, and clearance10.1021/acsnano.3c05853 ↗
24. The nano–intestine interaction: Understanding the location-oriented effects of engineered nanomaterials in the intestine10.1002/smll.201907665 ↗
25. The stomach in health and disease10.1136/gutjnl-2014-307595 ↗
26. Gastric microbes associated with gastric inflammation, atrophy and intestinal metaplasia 1 year after Helicobacter pylori eradication10.1136/gutjnl-2019-319826 ↗
27. An insight into gut microbiota and its functionalities10.1007/s00018-018-2943-4 ↗
28. The role of gastric microbiota in gastric cancer10.1080/19490976.2020.1762520 ↗
29. Helicobacter pylori infection and development of gastric cancer in Korea: Long-term follow-up10.1097/mcg.0b013e318046eac3 ↗
30. Sequential regimens for Helicobacter pylori eradication10.1016/s0140-6736(07)61455-x ↗
31. Biomaterials for Helicobacter pylori therapy: Therapeutic potential and future perspectives10.1080/19490976.2022.2120747 ↗
32. Decorating bacteria with a therapeutic nanocoating for synergistically enhanced biotherapy10.1002/smll.202101810 ↗
33. Antibiotic-induced changes in the intestinal microbiota and disease10.1016/j.molmed.2016.04.003 ↗
34. Emerging strategies for combating Fusobacterium nucleatum in colorectal cancer treatment: Systematic review, improvements and future challenges10.1002/exp.20230092 ↗
35. Gut microbiome and health: Mechanistic insights10.1136/gutjnl-2021-326789 ↗
36. Metabolic nanoregulator remodels gut microenvironment for treatment of inflammatory bowel disease10.1021/acsnano.3c11496 ↗
37. Specific surface modification of liposomes for gut targeting of food bioactive agents10.1111/1541-4337.13224 ↗
38. Dendrimers as pharmaceutical excipients: Synthesis, properties, toxicity and biomedical applications10.3390/ma13010065 ↗
39. An emerging class of amphiphilic dendrimers for pharmaceutical and biomedical applications: Janus amphiphilic dendrimers10.1016/j.ejps.2016.11.013 ↗
40. Nanomicelles: Types, properties and applications in drug delivery10.1049/nbt2.12018 ↗
41. The in vivo fate of polymeric micelles10.1016/j.addr.2022.114463 ↗
42. Current understanding of hydrogel for drug release and tissue engineering10.3390/gels8050301 ↗
43. Carbon-based hybrid nanogels: A synergistic nanoplatform for combined biosensing, bioimaging, and responsive drug delivery10.1039/c7cs00399d ↗
44. Milk-derived extracellular vesicles protect intestinal barrier integrity in the gut-liver axis10.1126/sciadv.ade5041 ↗
45. Extracellular vesicles as tools and targets in therapy for diseases10.1038/s41392-024-01735-1 ↗
46. Rapid intestinal uptake and targeted delivery to the liver endothelium using orally administered silver sulfide quantum dots10.1021/acsnano.9b06071 ↗
47. AuNPs as an important inorganic nanoparticle applied in drug carrier systems10.1080/21691401.2019.1687501 ↗
48. Gold nanoshell-linear tetrapyrrole conjugates for near infrared-activated dual photodynamic and photothermal therapies10.1021/acsomega.9b04150 ↗
49. Redox-responsive theranostic nanoplatforms based on inorganic nanomaterials10.1016/j.jconrel.2017.03.018 ↗
50. Rational design of liposomal drug delivery systems, a review: Combined experimental and computational studies of lipid membranes, liposomes and their pegylation10.1016/j.bbamem.2016.02.025 ↗
51. Investigating the application of liposomes as drug delivery systems for the diagnosis and treatment of cancer10.1155/2021/3041969 ↗
52. Krill oil-incorporated liposomes as an effective nanovehicle to ameliorate the inflammatory responses of DSS-induced colitis10.2147/ijn.s220053 ↗
53. Development of spleen targeting H2S donor loaded liposome for the effective systemic immunomodulation and treatment of inflammatory bowel disease10.1021/acsnano.2c08898 ↗
54. Nanocomposites-based targeted oral drug delivery systems with infliximab in a murine colitis model10.1186/s12951-020-00693-4 ↗
55. Solid lipid nanoparticles for duodenum targeted oral delivery of tilmicosin10.3390/pharmaceutics12080731 ↗
56. Dendrimer-based drug delivery systems: History, challenges, and latest developments10.1186/s13036-022-00298-5 ↗
57. Cutting-edge development in dendritic polymeric materials for biomedical and energy applications10.1016/j.eurpolymj.2021.110770 ↗
58. Graphene-dendrimer nanostars for targeted macrophage overexpression of metalloproteinase 9 and hepatic fibrosis precision therapy10.1021/acs.nanolett.8b02498 ↗
59. Highly efficient and tumor-selective nanoparticles for dual-targeted immunogene therapy against cancer10.1126/sciadv.aax5032 ↗
60. Oral supramolecular adsorbent for preventing chemo-induced gastrointestinal mucositis and microbial dysbiosis and for enhancing chemoimmunotherapy10.1002/adma.202205299 ↗
61. Polymeric micelles: Recent advancements in the delivery of anticancer drugs10.1007/s11095-015-1784-1 ↗
62. A multistage oral delivery system of PTX for improving oral bioavailability and enhancing anticancer efficacy10.1080/03639045.2021.1879831 ↗
63. Oral delivery of paclitaxel by polymeric micelles: A comparison of different block length on uptake, permeability and oral bioavailability10.1016/j.colsurfb.2019.110554 ↗
64. Acid-base transformative HADLA micelles alleviate colitis by restoring adaptive immunity and gut microbiome10.1016/j.jconrel.2023.10.039 ↗
65. Treatment of peanut allergy and colitis in mice via the intestinal release of butyrate from polymeric micelles10.1038/s41551-022-00972-5 ↗
66. Colonic delivery of vasoactive intestinal peptide nanomedicine alleviates colitis and shows promise as an oral capsule10.2217/nnm-2020-0280 ↗
67. Nanogels: Synthesis, properties, and recent biomedical applications10.1016/j.pmatsci.2023.101167 ↗
68. Injectable hydrogels for spinal cord injury repair10.1016/j.engreg.2022.09.001 ↗
69. Angiogenic microspheres for the treatment of a thin endometrium10.1021/acsbiomaterials.1c00615 ↗
70. An olsalazine nanoneedle-embedded inulin hydrogel reshapes intestinal homeostasis in inflammatory bowel disease10.1016/j.bioactmat.2023.10.028 ↗
71. Oral hydrogel microbeads-mediated in situ synthesis of selenoproteins for regulating intestinal immunity and microbiota10.1021/jacs.3c02179 ↗
72. A gas therapy strategy for intestinal flora regulation and colitis treatment by nanogel-based multistage no delivery microcapsules10.1002/adma.202309972 ↗
73. Platelet membrane fragment self-assembled oral hydrogel microspheres for restoring intestinal microvascular injury10.1002/adfm.202302007 ↗
74. Harnessing tissue-derived extracellular vesicles for osteoarthritis theranostics10.7150/thno.62708 ↗
75. Extracellular vesicle-loaded hydrogels for tissue repair and regeneration10.1016/j.mtbio.2022.100522 ↗
76. Extracellular vesicles of Fusobacterium nucleatum compromise intestinal barrier through targeting RIPK1-mediated cell death pathway10.1080/19490976.2021.1902718 ↗
77. Turmeric-derived nanovesicles as novel nanobiologics for targeted therapy of ulcerative colitis10.7150/thno.73650 ↗
78. An efficient method to isolate lemon derived extracellular vesicles for gastric cancer therapy10.1186/s12951-020-00656-9 ↗
79. Exosomes as drug delivery systems: A brief overview and progress update10.1016/j.ejpb.2020.07.026 ↗
80. Exosome-based bone-targeting drug delivery alleviates impaired osteoblastic bone formation and bone loss in inflammatory bowel diseases10.1016/j.xcrm.2022.100881 ↗
81. Therapeutic potential of exosome-based personalized delivery platform in chronic inflammatory diseases10.1016/j.ajps.2022.100772 ↗
82. Oral zero-valent-molybdenum nanodots for inflammatory bowel disease therapy10.1126/sciadv.abp9882 ↗
83. Acid-resistant near-infrared II Ag2Se quantum dots for gastrointestinal imaging10.1021/acs.analchem.3c01967 ↗
84. Biomaterial-based gene therapy10.1002/mco2.259 ↗
85. A review on the synthesis and functionalization of gold nanoparticles as a drug delivery vehicle10.2147/ijn.s279094 ↗
86. Self-assembled block copolymer [(BenzA)-b-(PCL)] micelles to orient randomly distributed AuNPs into hollow core-shell morphology and its role as payload for nanomedicines10.1016/j.msec.2018.07.033 ↗
87. Controllable gold nanocluster–emulsion interface for direct cell penetration and photothermal killing10.1002/adma.202208349 ↗
88. A porous Au@Rh bimetallic core–shell nanostructure as an H2O2-driven oxygenerator to alleviate tumor hypoxia for simultaneous bimodal imaging and enhanced photodynamic therapy10.1002/adma.202001862 ↗
89. Oriented boronate affinity–imprinted inverse opal hydrogel for glycoprotein assay via colorimetry10.1007/s00604-020-04320-9 ↗
90. Antibacterial structural color hydrogels10.1021/acsami.7b11258 ↗
91. Silica nanoparticles: A promising platform for enhanced oral delivery of macromolecules10.1016/j.jconrel.2020.07.021 ↗
92. Gastro-protective protein-silica nanoparticles formulation for oral drug delivery: In vitro release, cytotoxicity and mitochondrial activity10.1016/j.ejpb.2020.03.015 ↗
93. A facile way to improve the bioavailability of nanomedicine based on the threshold theory10.1021/acs.molpharmaceut.2c00137 ↗
94. Biodegradable polymeric nanoparticles loaded with flavonoids: A promising therapy for inflammatory bowel disease10.3390/ijms24054454 ↗
95. A composite nanocarrier to inhibit precipitation of the weakly basic drug in the gastrointestinal tract10.1080/10717544.2020.1760402 ↗
96. Nanoparticle-assembled bioadhesive coacervate coating with prolonged gastrointestinal retention for inflammatory bowel disease therapy10.1038/s41467-021-27463-6 ↗
97. Rod-like mesoporous silica nanoparticles facilitate oral drug delivery via enhanced permeation and retention effect in mucus10.1007/s12274-022-4601-2 ↗
98. The intracellular fate and transport mechanism of shape, size and rigidity varied nanocarriers for understanding their oral delivery efficiency10.1016/j.biomaterials.2023.121995 ↗
99. Tannic acid and zinc ion coordination of nanase for the treatment of inflammatory bowel disease by promoting mucosal repair and removing reactive oxygen and nitrogen species10.1016/j.actbio.2024.02.015 ↗
100. Silencing of intestinal glycoprotein Cd98 by orally targeted nanoparticles enhances chemosensitization of colon cancer10.1021/acsnano.7b08499 ↗